Results 51 to 60 of about 172,693 (257)

Mediation Analysis with Survival Outcomes: Accelerated Failure Time Versus Proportional Hazards Models

Frontiers in Psychology, 2016
Objective: Survival time is an important type of outcome variable in treatment research. Currently, limited guidance is available regarding performing mediation analyses with survival outcomes, which generally do not have normally distributed errors, and
Lois A Gelfand, David P MacKinnon, Robert J DeRubeis, Amanda N Baraldi   +3 more
doaj   +1 more source

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

Prediction Intervals for the Failure Time of Prestressed Concrete Beams

Advances in Materials Science and Engineering, 2016
The aim is the prediction of the failure time of prestressed concrete beams under low cyclic load. Since the experiments last long for low load, accelerated failure tests with higher load are conducted.
Sebastian Szugat, Jens Heinrich, Reinhard Maurer, Christine H. Müller   +3 more
doaj   +1 more source

Kernel based methods for accelerated failure time model with ultra-high dimensional data

BMC Bioinformatics, 2010
Background Most genomic data have ultra-high dimensions with more than 10,000 genes (probes). Regularization methods with L1 and Lp penalty have been extensively studied in survival analysis with high-dimensional genomic data.
Jiang Feng, Tan Ming, Chen Dechang, Liu Zhenqiu, Gartenhaus Ronald B   +4 more
doaj   +1 more source

Regular Variation and the Identification of Generalized Accelerated Failure-Time Models [PDF]

SSRN Electronic Journal, 2011
Ridder (1990,Review of Economic Studies57, 167–182) provides an identification result for the Generalized Accelerated Failure-Time (GAFT) model. We point out that Ridder’s proof of this result is incomplete, and provide an amended proof with an additional necessary and sufficient condition that requires that a function varies regularly at 0 and ∞.
Abbring, J.H., Ridder, G.
openaire   +7 more sources

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Demographic translation and tempo effects: An accelerated failure time perspective

Demographic Research, 2006
In this paper I review the concept of tempo effects in demography, focusing on the tempo adjustments proposed by Bongaarts and Feeney and drawing on the work of Ryder and Zeng and Land.
Germán Rodriguez
doaj  

Analysis of Life Insurance Contract Cancellations Using the Accelerated Failure Time Model [PDF]

Statistika: Statistics and Economy Journal
The aim of this paper is to analyse the cancellation of life insurance contracts on death using an accelerated failure time (AFT) model. The study focuses on identifying risk factors that influence the time to cancellation, with the objective of ...
Vladimír Mucha, Patrícia Ďuďák Teplanová, Ján Gogola, Jana Špirková   +3 more
doaj   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source